17 November 2017 - - US-based immunotherapies developer IRX Therapeutics, Inc. has appointed Luba Greenwood, vice president of global business development and mergers and acquisitions at F. Hoffmann-La Roche, Diagnostics, to its board of directors, the company said.
Greenwood brings a wealth of pharmaceutical and biotechnology industry experience, and expertise in building innovative technology companies and providing strategic counsel to global corporations. Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting, and operations.
Greenwood recently served as Venture Partner at Colt Ventures, and led business development and strategy for Pronutria, a Flagship VenturesLabs company. Prior to that, she served as Senior Mergers and acquisitions Counsel at Pfizer Inc.
Greenwood is an adjunct professor at Boston University School of Management where she teaches business law, and Boston University Law School where she teaches a course on life sciences. She received a J.D. from Northeastern University and a B.A. from Brandeis University.
IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor.